- /
- Supported exchanges
- / US
- / ELTX.NASDAQ
Elicio Therapeutics Inc. (ELTX NASDAQ) stock market data APIs
Elicio Therapeutics Inc. Financial Data Overview
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Elicio Therapeutics Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Elicio Therapeutics Inc. data using free add-ons & libraries
Get Elicio Therapeutics Inc. Fundamental Data
Elicio Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -37 738 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Elicio Therapeutics Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Elicio Therapeutics Inc. News
New
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics Inc. BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generati...
Elicio Therapeutics Enters $15 Mln Offering Of Shares For ELI-002 7P; Stock Down
(RTTNews) - Elicio Therapeutics, Inc. (ELTX), a clinical-stage biotechnology company, announced that it has entered into a definitive securities purchase agreement with two institutional investors and...
Elicio Therapeutics drops 5%, prices $15M direct offering
* Elicio Therapeutics (ELTX [https://seekingalpha.com/symbol/ELTX]) priced [https://seekingalpha.com/pr/20571020-elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering] a $15...
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherap...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.